Objective To evaluate the efficacy,safety,and biocompatibility of a posterior chamber phakic intraocular lens (PCPIOL) to correct high myopia within 1 year.Methods In a retrospective case series study,an implantable intraocular lens was implanted in 290 eyes of 149 patients with a mean age of 29.0±6.5 years (range 20 to 49 years).There were 107 eyes from males and 183 eyes from females.Mean preoperative myopia was-13.2±5.6 D (range-6.0 to-32.0 D).The follow-up included tests for visual acuity,intraocular pressure,manifest refraction,and adverse reactions.Results Postoperatively,all eyes had a significant increase in uncorrected visual acuity (UCVA).Best corrected visual acuity (BCVA) had improved by 1 or more lines in 199 eyes (68.6%)at 1 year.No eye lost BCVA.Thirty-two eyes developed intraocular pressure (IOP) more than 35 mmHg within 3 hours after the implatation.Pupillary blockage caused an increase in IOP in 13 eyes and insufficient removal of viscoelastic material caused an increase in 19 eyes.IOP returned to normal in the following days after quick treatment.Three eyes had intraocular pressure between 21-25 mmHg.Two eyes had macular hemorrhage 3 months after the implantation,and the hemorrhage regressed 3 month later.Throe IOLs were removed from 2 patients because of an intolerant halo.The IOLs were exchanged in 12 eyes in 1 year because of high or low vault.Conclusion After 1 year of follow-up,IOL implantation had good visual and refractive results with excellent biocompatibility and fewer adverse reactions.